"Our thinking is in the fall, we need to be ready to do what our customer wants," Trizzino said, referring to the U.S. Trizzino, during the Bank of America interview, said the goal is to have the shots ready by October for a fall vaccination campaign should the FDA decide to move forward with updating the shots. Novavax plans to launch a clinical trial this month on a version of the vaccine that targets omicron mutations, Erck said during the company's earnings call. As the virus has evolved, the shots have become less effective at blocking infections. All of the current vaccines, including Novavax, target the spike protein of the original strain of the virus that emerged in Wuhan, China, in 2019. It's unclear, however, when the FDA may consider the company's shots for teens and as booster doses.įDA authorization of the vaccine would come right as the drug regulator is considering redesigning Covid shots this fall to target mutations the virus has developed over the past two years. Novavax has submitted its data from teenagers to the FDA and is also filing data on booster doses, Chief Medical Officer Philip Dubovsky said during the company's earnings call. Trizzino said the shots could also play an important role as booster doses and in teenagers ages 12 to 17. Novavax's vaccine uses more conventional protein technology, whereas Pfizer's and Moderna's use messenger RNA platforms first authorized during the coronavirus pandemic. Trizzino said on Wednesday that Novavax's shots would offer choice to the remainder of the adult population that would prefer not to receive an mRNA vaccine. market at a time when 76% of adults are already fully vaccinated. Pfizer, Moderna and Johnson & Johnson are the three vaccines currently used in the U.S., and the FDA last week limited the use of J&J's shots. If Novavax's vaccine is authorized by the FDA, it will be first new shot to hit the market in the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |